Table 1: Investigation, targeted agents used in study.

AgentMechanism of actionSourceAgreement

ABT-888PARP inhibitorAbbVie*Single agent and with FDA approved
DasatinibSrc, BCR-ABL inhibitorBMS*Single agent and with topoisomerase inhibitors or GX15-070
EtoposideTopoisomerase II inhibitorCommercialFDA approved
GX15-070BH3 mimeticGeminX*Single agent and with dasatinib or PXD101, and FDA approved
MK-2206Akt inhibitorMerckSingle agent and with dasatinib, MK-8669 or FDA approved
MK-8669mTor inhibitorMerckSingle agent and with dasatinib, MK-2206 or FDA approved
PXD101HDAC inhibitorCuraGen*Single agent and with GX15-070
Saracatinib (AZD0530)Src inhibitorAstraZeneca*Single agent and with saracatinib
Selumetinib
(AZD6244, ARRY-142886)
MEK-1/2 inhibitorAstraZeneca*Single agent and with saracatinib and FDA approved
SorafenibVEGF, RAF inhibitorCommercialFDA approved
TopotecanTopoisomerase I inhibitorCommercialFDA approved
TriciribineAKT inhibitor, nucleosideCommercialFDA approved
Vorinostat HDAC inhibitorMerck*FDA approved

 *Obtained through CTEP N01-CM-62208.